Using the drop-down menu below, read about highlighted scientific news for patients from ASCO's Annual Meetings, Symposia, and medical journals for the past three years. You can select a specific year, meeting or publication, and/or a specific topic, such as a type of cancer. Selecting "All" will take you to a complete list of articles that appear under all categories.
This includes ASCO’s Journal of Clinical Oncology and its scientific meetings, including the ASCO Annual Meeting, a five-day meeting held each May/June. To read the Annual Meeting summaries compiled into a yearly newsletter, you can also review Research Round Up: News for Patients from the ASCO Annual Meeting. Don’t forget to check out audio podcasts and videos about this news, as well. And a list of upcoming Symposia can be found here. And, in addition to the highlighted studies below, thousands of scientific abstracts are released each year at different ASCO meetings. To search the entire collection of meeting abstracts, visit ASCO's website.
Giving either of two newer and more costly drugs, nanoparticle albumin-bound paclitaxel (Abraxane; called nab-paclitaxel) and ixabepilone (Ixempra), did not work better to treat locally advanced or metastatic breast cancer than standard chemotherapy with paclitaxel, according to a large study. Locally advanced breast cancer is cancer that has spread to parts of the body near the breast. Metastatic breast cancer has spread to other, more distant parts of the body.
According to a recent study, women survivors of childhood cancers who received low doses of radiation therapy aimed at the chest had a high risk of developing breast cancer at a young age. An increased risk of breast cancer is a known long-term side effect or late effect of moderate to high-dose radiation therapy to the chest. That is why the current screening recommendations for childhood cancer survivors recommend annual breast cancer screening for women who received moderate to high doses (20 or more Gray or Gy, a measure of the radiation dose) of radiation therapy to the chest. This study shows that even childhood cancer survivors who received lower doses of radiation therapy have a higher risk of breast cancer, and they may need to follow similar breast cancer screening recommendations.
A study in Germany showed that it is possible for local community hospitals to test non-small cell lung cancer (NSCLC) for molecular factors involved in the cancer. This means that a greater number of patients will have access to these tests. These molecular factors can be genes, proteins, or features of the tissue environment that contribute to cancer growth and survival. The results of tests for molecular factors often determine whether targeted therapy is a treatment option. Targeted therapy is a treatment that targets the molecular factors involved in cancer growth.
A recent study showed that the drug trametinib slowed tumor growth and lengthened the lives of patients who have advanced melanoma with a BRAF gene mutation (change). Trametinib is a type of treatment called targeted therapy. Targeted therapy targets the cancer's specific genes, proteins, or the tissue environment that contributes to cancer growth and survival. Currently, there is one targeted therapy approved to treat melanoma that targets the BRAF gene, called vemurafenib (Zelboraf). However, vemurafenib eventually stops controlling melanoma growth for most patients, highlighting the need for other treatment options. Trametinib targets the MEK protein, which affects melanoma growth similarly to a mutated BRAF gene, which is why researchers are studying this treatment for melanoma.
In a recent study, researchers found that the new drug trastuzumab emtansine (T-DM1) worked better to control the growth of HER2-positive metastatic breast cancer than the current standard treatment. HER2-positive metastatic breast cancer is breast cancer that has spread to other parts of the body and has too much of a protein called human epidermal growth factor receptor 2 (HER2). The current standard treatment for this type of breast cancer is chemotherapy with capecitabine (Xeloda) combined with the targeted therapy lapatinib (Tykerb). Targeted therapy is a treatment that targets the cancer's specific genes, proteins, or the tissue environment that contributes to cancer growth and survival.
A long-term study comparing two common hormone therapy schedules showed that intermittent (short breaks in treatment) hormone therapy is less effective than continuous (no breaks in treatment) hormone therapy for men with hormone-sensitive prostate cancer with minimal disease spread (cancer that has not spread beyond the spine, pelvis, and lymph nodes). Hormone-sensitive prostate cancer is cancer that uses male sex hormones called androgens, such as testosterone, to grow and spread. Hormone therapy, also called androgen ablation or androgen-deprivation therapy, lowers levels of androgens in the body to help keep the cancer from growing or spreading. Eventually, metastatic prostate cancer (cancer that has spread) develops a resistance to hormone therapy, meaning the treatment stops working to control the cancer's growth.
Researchers found that continuing bevacizumab (Avastin) while switching the chemotherapy used for second-line treatment lengthened the lives of patients with metastatic (cancer that has spread) colorectal cancer who had already received bevacizumab and another type of chemotherapy, a new study showed. Second-line treatment is treatment given after the first treatment, called first-line treatment, has stopped working. This approach has been used in the United States, and this study confirms its use as an effective treatment method.
A large national survey of people with cancer showed that a patient's income strongly predicts whether he or she will participate in a clinical trial. A clinical trial is a research study involving people. A clinical trial may focus on new treatments, new methods to prevent cancer, and ways to manage the symptoms and side effects of cancer and cancer treatment.
A long-term study shows that a combination of bendamustine (Treanda) and rituximab (Rituxan) keeps two uncommon types of non-Hodgkin lymphoma (NHL), indolent (slow-growing) lymphoma and mantle cell lymphoma, from worsening longer than standard chemotherapy. Bendamustine and rituximab are drugs called targeted therapies. Targeted therapy is a treatment that targets the cancer's specific genes, proteins, or the tissue environment that contributes to cancer growth and survival.
A recent study by the European Organisation for Research and Treatment of Cancer (EORTC) shows that chemotherapy after radiation therapy slowed the growth of anaplastic oligodendroglial tumors (a type of brain tumor). It also lengthened the lives of patients with this type of tumor, especially for those whose tumor was missing specific genetic material in chromosomes 1 and 19 (called 1p/19q co-deletions). Currently, most patients with this disease receive either chemotherapy or radiation therapy, but not both.